Certain aspects of the present invention relate to modified hemoglobin proteins comprising at least one modification (e.g., at the thiol group of an exogenous amino acid residue) for homogenous conjugation of one or more polymeric moieties e.g. polyethylene glycol or derivatives thereof. Also included herein are methods of using such modified proteins and compositions comprising such proteins, e.g. in therapy.

This disclosure describes devices, systems, and methods related to oxygenated hemoglobin, the generation thereof, and the use thereof. An exemplary oxygenated hemoglobin therapy system includes an oxygen source configured to provide oxygen and a hemoglobin source configured to provide topical hemoglobin. The therapy system may also include a mixer which has a first inlet, a second inlet, and an outlet. The mixer is configured to mix the oxygen and the topical hemoglobin to form a mixture and to provide the mixture to a dressing via the outlet. The therapy system may further include the dressing. The oxygenated hemoglobin therapy systems described herein are suitable for use in medical devices, such as bandages, drapes, dressings, and wound closures.

This disclosure describes devices, systems, and methods related to oxygenated hemoglobin, the generation thereof, and the use thereof. An exemplary oxygenated hemoglobin therapy system includes an oxygen source configured to provide oxygen and a hemoglobin source configured to provide topical hemoglobin. The therapy system may also include a mixer which has a first inlet, a second inlet, and an outlet. The mixer is configured to mix the oxygen and the topical hemoglobin to form a mixture and to provide the mixture to a dressing via the outlet. The therapy system may further include the dressing. The oxygenated hemoglobin therapy systems described herein are suitable for use in medical devices, such as bandages, drapes, dressings, and wound closures.

Methods for making hemoglobin based blood substitute preparations and hemoglobin based blood substitute preparations. The methods involve preparing a low purity erythrocyte protein fraction comprising hemoglobin protein and endogenous non-hemoglobin protein complement, and chemically modifying the proteins in the protein fraction to form a cross-linked hemoglobin containing blood substitute preparation. The low purity erythrocyte protein preparation can contain from at least about 0.2% (mole/mole) up to about 20% (mole/mole) endogenous non-hemoglobin protein complement. At least about 90% (mole/mole) of the hemoglobin proteins can be cross-linked, so that the average molecular mass of cross-linked proteins comprising hemoglobin protein molecules in the preparation is at least about 300 kDa. The preparations can be used to prepare finished blood substitute formulations for in-vivo and ex-vivo use.

Methods for making hemoglobin based blood substitute preparations and hemoglobin based blood substitute preparations. The methods involve preparing a low purity erythrocyte protein fraction comprising hemoglobin protein and endogenous non-hemoglobin protein complement, and chemically modifying the proteins in the protein fraction to form a cross-linked hemoglobin containing blood substitute preparation. The low purity erythrocyte protein preparation can contain from at least about 0.2% (mole/mole) up to about 20% (mole/mole) endogenous non-hemoglobin protein complement. At least about 90% (mole/mole) of the hemoglobin proteins can be cross-linked, so that the average molecular mass of cross-linked proteins comprising hemoglobin protein molecules in the preparation is at least about 300 kDa. The preparations can be used to prepare finished blood substitute formulations for in-vivo and ex-vivo use.

The present disclosure provides improved multiplex genome editing compositions and methods. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.

A therapeutic hemoglobin-based oxygen carrier solution is formed by directly combining at least one of freeze-dried platelets and freeze-drug plasma with a hemoglobin-based oxygen carrier. The therapeutic hemoglobin-based oxygen carrier solution can be employed to treat bleeding or anemia and simultaneously increase systemic convective oxygen delivery in a subject suffering low circulatory oxygen transport or bleeding.

A therapeutic hemoglobin-based oxygen carrier solution is formed by directly combining at least one of freeze-dried platelets and freeze-drug plasma with a hemoglobin-based oxygen carrier. The therapeutic hemoglobin-based oxygen carrier solution can be employed to treat bleeding or anemia and simultaneously increase systemic convective oxygen delivery in a subject suffering low circulatory oxygen transport or bleeding.

A therapeutic hemoglobin-based oxygen carrier solution is formed by directly combining at least one of freeze-dried platelets and freeze-drug plasma with a hemoglobin-based oxygen carrier. The therapeutic hemoglobin-based oxygen carrier solution can be employed to treat bleeding or anemia and simultaneously increase systemic convective oxygen delivery in a subject suffering low circulatory oxygen transport or bleeding.

Described herein are compositions for use in medicine as anti-ischemic organ storage and perfusion solutions.